COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

The Protective Effects of Sevoflurane in Pediatric Cardiac Surgery

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01450956
Recruitment Status : Unknown
Verified November 2011 by Xijing Hospital.
Recruitment status was:  Recruiting
First Posted : October 13, 2011
Last Update Posted : November 28, 2011
Information provided by (Responsible Party):
Xijing Hospital

Brief Summary:
During repair of a congenital heart defect the child is exposed to myocardial hypoxia. Recent studies have suggested that the paediatric myocardium is more sensitive to hypoxia and cardioplegic arrest than the adult. The protective effect of halogenated agents on ischaemia and reperfusion injury has been investigated widely in adults. The investigators hypothesis that sevoflurane applied during cardiopulmonary bypass might afford better myocardial protection during paediatric cardiac surgery.

Condition or disease Intervention/treatment Phase
Congenital Heart Diseases Drug: Sevoflurane Other: Control Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 100 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: The Protective Effects of Sevoflurane Application During CPB on Pediatric Patients Underwent Cardiac Surgery: a Randomized, Controlled, Blinded Clinical Trial
Study Start Date : September 2011
Estimated Primary Completion Date : January 2012
Estimated Study Completion Date : January 2012

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Heart Surgery
Drug Information available for: Sevoflurane

Arm Intervention/treatment
Experimental: Sevoflurane
Patients will receive 2% sevoflurane via oxygenator during CPB
Drug: Sevoflurane
Sevoflurane will be given at a concentration of 2% through oxygenator during CPB

No Intervention: Control
Patients will receive only oxygen and air through oxygenator
Other: Control
Patients will receive only oxygen and air through oxygenator

Primary Outcome Measures :
  1. all cause mortality [ Time Frame: within the first 30 days (plus or minus 3 days) after surgery ]
    All cause mortality after the cardaic surgery, patients will be followed up for 30 days

Secondary Outcome Measures :
  1. serum cTnI concentrations [ Time Frame: 48 h after the surgery ]
    serial serum cTnI concentrations will be determined to whether sevoflurane application during CPB will decrease the cTnI release after operation.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   1 Month to 24 Months   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • pediatric patients (body weight < 10 kg)
  • diagnosed with congenital heart diseases
  • scheduled for repair operation with CPB
  • in the Department of Cardiovascular Surgery, Xijing Hospital

Exclusion Criteria:

  • systemic infections
  • other systemic diseases

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01450956

Layout table for location contacts
Contact: Zhenxiao Jin, Ph.D 86-29-84771022

Layout table for location information
China, Shaanxi
Department of Cardiovascular Surgery, Xijing Hospital Recruiting
Xi'an, Shaanxi, China, 710032
Contact: Zhenxiao Jin, PhD    86-29-84771022   
Sub-Investigator: Hongyan Xiong, MD         
Sponsors and Collaborators
Xijing Hospital
Layout table for investigator information
Principal Investigator: Zhenxiao Jin, PhD Department of Cardiovascular Surgery, Xijing Hospital
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Xijing Hospital Identifier: NCT01450956    
Other Study ID Numbers: XJXZ2011-010
First Posted: October 13, 2011    Key Record Dates
Last Update Posted: November 28, 2011
Last Verified: November 2011
Keywords provided by Xijing Hospital:
congenital heart diseases
cardiopulmonary bypass
Additional relevant MeSH terms:
Layout table for MeSH terms
Heart Diseases
Cardiovascular Diseases
Platelet Aggregation Inhibitors
Anesthetics, Inhalation
Anesthetics, General
Central Nervous System Depressants
Physiological Effects of Drugs